Matt Badiali Speaks about Freedom Checks

In the recent times, American media houses introduced something that has left many people in the country talking. If you have been watching your television, you must have come across Freedom Checks. This is the new name in town, and people from all walks of life are speaking about it. In one of the adverts showing Freedom Checks, an influential finance executive who uses the name Matt Badiali is seen holding a huge check showing over one hundred thousand dollars. The checks in Matt Badiali’s hand looks like the checks that are issued by the American government for any tax refund. Most people have been wondering and asking if they could consider investing in freedom checks so that they can earn some extra money and change their financial situation. Visit streetwisereports.com to know more.

Although Matt is a top investor in the American market, there are very many viewers who have decided that they are going to ignore the advert because it resembles all the other scams that have been introduced by the modern technology. There are investors who believe that when the deal is too good, the chances of getting scammed are high. These individuals say that this deal being shown in the media is too good, and it can never be the true one. The scheme shows that the ordinary American can get rich very quickly without having to spend many hours in the office. The nature of this ad has been shocking many. Most people say that the American government can never write a check for a citizen just for accomplishing nothing. For many, this act is impossible.

Freedom Checks have not been understood in the market, and this is probably one of the reasons they have been getting negative results from most consumers. There are few individuals who do not know who Badiali is and why he should be trusted. The businessman is one of the influential figures who work with Banyan Hill Publishing. Matt Badiali is an expert when it comes to natural resources, and he can assist anyone to earn wealth and live their dream life. Matt now wants to clear the air and answer the question in the minds of many people. According to Matt Badiali, Freedom Checks are the perfect way of earning wealth, and they are not scams as many people believe. Investors do not have to worry about losing their money when investing in freedom checks. Follow: https://twitter.com/Matt_B_Guru

Eric Lefkofsky Chicago’s new unicorn tech company

Three years ago, Eric Lefkofsky combined his expertise as an entrepreneur and knowledge in the technology industry to co-found Tempus, a new Chicago startup company. From first-hand experience, Eric learned that healthcare databases were small and disorganized. Having gained the expertise from he’s dealing with other technology platforms, he knew this was the platform that was needed to open a wider door for the healthcare industry. So Lefkofsky and his longtime friend and business partner Brad Keywell created Tempus Labs. Staff and teams of technology, data-science and cancer research experts were hired. Partnerships were developed with academic medical centers and cancer physicians.

The mission of Tempus was to innovate the way physicians thought and treated cancer. Their goal was to provide physicians a learning library of data from previous cancer patients. Data that not only contains patient history but analyzed data of physicians diagnose and treatments. Data that enables physicians to deliver an integrated treatment program that would be beneficial to patient outcome. Lefkofsky confirmed that Tempus has partnered with the University of Chicago, Rush University and Northwestern, as well as, over 50 other research hospitals, Cancer Institutes/Centers and drug companies across the United States.

In this short time, Tempus has grown to become one of Chicago’s top ten health tech companies. And after the latest round of funding in March 2018 this new startup is now the latest of Chicago’s “unicorn” tech company. In September of last year Tempus raised $70 million, and everyone thought it was an impressive feat. In March of this year the startup raised $80 million, raising the company’s value to $1.1 billion, bringing it to it’s “unicorn” status. This increase of highly needed investment money will cause a rolling effect of more hires of high tech personnel, increased research and more data collecting, to physicians more acutely customizing cancer treatment care. For cancer patients, it means instead of just focusing on their cancer, treatments are focused on them as a whole being.

Tempus has already aggregated the largest clinical cancer database, putting structure into the unstructured digital medical records systems. As Tempus continues to develop a model for collecting critic medical data and proving it can be done, the future looks bright for patients with other hard to treat diseases.

https://www.bloomberg.com/research/stocks/people/person.asp?personId=166953&privcapId=82311805